Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis

被引:276
作者
Devy, Laetitia [1 ]
Huang, Lili [1 ]
Naa, Laurent [2 ]
Yanamandra, Niranjan [1 ]
Pieters, Henk [2 ]
Frans, Nicolas [2 ]
Chang, Edward [1 ]
Tao, Qingfeng [1 ]
Vanhove, Marc [2 ]
Lejeune, Annabelle [2 ]
van Gool, Reinoud [2 ]
Sexton, Daniel J. [1 ]
Kuang, Guannan [1 ]
Rank, Douglas [1 ]
Hogan, Shannon [1 ]
Pazmany, Csaba [1 ]
Ma, Yu Lu [1 ]
Schoonbroodt, Sonia [2 ]
Nixon, Andrew E. [1 ]
Ladner, Robert C. [1 ]
Hoet, Rene [2 ]
Henderikx, Paula [2 ]
TenHoor, Chris [1 ]
Rabbani, Shafaat A. [3 ]
Valentino, Maria Luisa [3 ]
Wood, Clive R. [1 ]
Dransfield, Daniel T. [1 ]
机构
[1] Dyax Corp, Cambridge, MA 02139 USA
[2] Dyax SA, Liege, Belgium
[3] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ, Canada
关键词
OVARIAN-CARCINOMA CELLS; BREAST-CANCER; MICE DEFICIENT; MT1-MMP; EXPRESSION; METASTASIS; ACTIVATION; GENERATION; ANTIBODIES; AFFINITY;
D O I
10.1158/0008-5472.CAN-08-3255
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inhibition of specific matrix metalloproteinases (MNIP) is an attractive noncytotoxic approach to cancer therapy. MMP-14, a membrane-bound zinc endopeptidase, has been proposed to play a central role in tumor growth, invasion, and neovascularization. Besides cleaving matrix proteins, MMP-14 activates proMMP-2 leading to an amplification of pericellular proteolytic activity. To examine the contribution of MMP-14 to tumor growth and angiogenesis, we used DX-2400, a highly selective fully human MMP-14 inhibitory antibody discovered using phage display technology. DX-2400 blocked proMMP-2 processing on tumor and endothelial cells, inhibited angiogenesis, and slowed tumor progression and formation of metastatic lesions. The combination of potency, selectivity, and robust in vivo activity shows the potential of a selective MMP-14 inhibitor for the treatment of solid tumors. [Cancer Res 2009;69(4):1517-26]
引用
收藏
页码:1517 / 1526
页数:10
相关论文
共 40 条
[1]   Matrix metalloproteinases:: New routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease [J].
Arroyo, A. G. ;
Genis, L. ;
Gonzalo, P. ;
Matias-Roman, S. ;
Pollan, A. ;
Galvez, B. G. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (17) :1787-1802
[2]   Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression [J].
Barbolina, Maria V. ;
Adley, Brian P. ;
Ariztia, Edgardo V. ;
Liu, Yueying ;
Stack, M. Sharon .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (07) :4924-4931
[3]   MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D [J].
Basile, John R. ;
Holmbeck, Kenn ;
Bugge, Thomas H. ;
Gutkind, J. Silvio .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (09) :6899-6905
[4]   Inhibition of angiogenesis and invasion in malignant gliomas [J].
Chi, Andrew ;
Norden, Andrew D. ;
Wen, Patrick Y. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (11) :1537-1560
[5]   MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix [J].
Chun, TH ;
Sabeh, F ;
Ota, I ;
Murphy, H ;
McDonagh, KT ;
Holmbeck, K ;
Birkedal-Hansen, H ;
Allen, ED ;
Weiss, SJ .
JOURNAL OF CELL BIOLOGY, 2004, 167 (04) :757-767
[6]  
Copeland RA, 2000, J PHARM SCI, V89, P1000, DOI 10.1002/1520-6017(200008)89:8<1000::AID-JPS4>3.0.CO
[7]  
2-1
[8]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[9]  
Della Porta P, 1999, ANTICANCER RES, V19, P3809
[10]   Preclinical and clinical studies of MMP inhibitors in cancer [J].
Drummond, AH ;
Beckett, P ;
Brown, PD ;
Bone, EA ;
Davidson, AH ;
Galloway, WA ;
Gearing, AJH ;
Huxley, P ;
Laber, D ;
McCourt, M ;
Whittaker, M ;
Wood, LM ;
Wright, A .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC APPLICATIONS, 1999, 878 :228-235